Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis
| dc.contributor.advisor | Okpechi, Ikechi Gareth | |
| dc.contributor.advisor | Omar, Fierdoz | |
| dc.contributor.author | Rusch, Jody Alan | |
| dc.date.accessioned | 2021-09-15T09:37:36Z | |
| dc.date.available | 2021-09-15T09:37:36Z | |
| dc.date.issued | 2020 | |
| dc.date.updated | 2021-09-15T09:06:10Z | |
| dc.description.abstract | Background: Renal involvement is common in systemic lupus erythematosus (SLE) and can lead to chronic kidney disease (CKD). Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. Due to its invasiveness, repeat renal biopsy for monitoring disease activity is not recommended, thus creating a need for noninvasive and accurate biomarkers. Monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-like weak inducer of apoptosis (TWEAK) have been implicated in the pathogenesis of LN and are thus potential biomarkers for disease activity monitoring. Methods: In this study urinary MCP-1 (uMCP-1) and TWEAK (uTWEAK), together with standard markers of disease activity, were analysed in a cohort of 50 biopsy-proven LN patients at baseline, after sixmonths of induction therapy, and at one-year. Results: Throughout the study there was correlation between uMCP-1 and uTWEAK (r=0.52, p< 0.001). Both biomarkers also correlated with standard of care tests and clinical scores. The median [interquartile range] of uMCP-1 and uTWEAK were significantly increased in the active group when compared to the quiescent group (1440 [683–2729] vs 256 [175–477] pg/mL, p< 0.0001, and 209 [117–312] vs 74 [11– 173] pg/mL, p=0.0008, respectively). After completion of induction therapy in the active group, there was no significant difference in biomarker results between the groups. The sensitivity and specificity for indicating disease activity was 95% and 73% for uMCP-1 (area under curve [AUC]=0.875), and 60% and 90% for uTWEAK (AUC=0.783), respectively. Conclusion: uMCP-1 and uTWEAK reflect LN disease activity, and correlate with standard of care biomarkers in a South African cohort. Further studies are needed to assess additional clinical benefit. | |
| dc.identifier.apacitation | Rusch, J. A. (2020). <i>Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis</i>. (). ,Faculty of Health Sciences ,Division of Chemical Pathology. Retrieved from http://hdl.handle.net/11427/33899 | en_ZA |
| dc.identifier.chicagocitation | Rusch, Jody Alan. <i>"Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis."</i> ., ,Faculty of Health Sciences ,Division of Chemical Pathology, 2020. http://hdl.handle.net/11427/33899 | en_ZA |
| dc.identifier.citation | Rusch, J.A. 2020. Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis. . ,Faculty of Health Sciences ,Division of Chemical Pathology. http://hdl.handle.net/11427/33899 | en_ZA |
| dc.identifier.ris | TY - Master Thesis AU - Rusch, Jody Alan AB - Background: Renal involvement is common in systemic lupus erythematosus (SLE) and can lead to chronic kidney disease (CKD). Diagnosis of lupus nephritis (LN) is dependent on renal biopsy. Due to its invasiveness, repeat renal biopsy for monitoring disease activity is not recommended, thus creating a need for noninvasive and accurate biomarkers. Monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-like weak inducer of apoptosis (TWEAK) have been implicated in the pathogenesis of LN and are thus potential biomarkers for disease activity monitoring. Methods: In this study urinary MCP-1 (uMCP-1) and TWEAK (uTWEAK), together with standard markers of disease activity, were analysed in a cohort of 50 biopsy-proven LN patients at baseline, after sixmonths of induction therapy, and at one-year. Results: Throughout the study there was correlation between uMCP-1 and uTWEAK (r=0.52, p< 0.001). Both biomarkers also correlated with standard of care tests and clinical scores. The median [interquartile range] of uMCP-1 and uTWEAK were significantly increased in the active group when compared to the quiescent group (1440 [683–2729] vs 256 [175–477] pg/mL, p< 0.0001, and 209 [117–312] vs 74 [11– 173] pg/mL, p=0.0008, respectively). After completion of induction therapy in the active group, there was no significant difference in biomarker results between the groups. The sensitivity and specificity for indicating disease activity was 95% and 73% for uMCP-1 (area under curve [AUC]=0.875), and 60% and 90% for uTWEAK (AUC=0.783), respectively. Conclusion: uMCP-1 and uTWEAK reflect LN disease activity, and correlate with standard of care biomarkers in a South African cohort. Further studies are needed to assess additional clinical benefit. DA - 2020_ DB - OpenUCT DP - University of Cape Town KW - Chemical Pathology KW - Nephrology LK - https://open.uct.ac.za PY - 2020 T1 - Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis TI - Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis UR - http://hdl.handle.net/11427/33899 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/33899 | |
| dc.identifier.vancouvercitation | Rusch JA. Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis. []. ,Faculty of Health Sciences ,Division of Chemical Pathology, 2020 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/33899 | en_ZA |
| dc.language.rfc3066 | eng | |
| dc.publisher.department | Division of Chemical Pathology | |
| dc.publisher.faculty | Faculty of Health Sciences | |
| dc.subject | Chemical Pathology | |
| dc.subject | Nephrology | |
| dc.title | Using urinary MCP-1 and TWEAK to assess disease activity in a cohort of South African patients with lupus nephritis | |
| dc.type | Master Thesis | |
| dc.type.qualificationlevel | Masters | |
| dc.type.qualificationlevel | MMed |